scholarly journals e0635 The evaluation to the efficacy and safety of tirofiban in acute coronary syndrome patients with clopidogrel resistance during percutaneous coronary intervention

Heart ◽  
2010 ◽  
Vol 96 (Suppl 3) ◽  
pp. A196-A196
Author(s):  
F. Xianghua ◽  
G. Xinshun ◽  
C. Qiaoying ◽  
F. Weize ◽  
Z. Jing ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Coronary Intervention ◽  
Efficacy And Safety ◽  
Clopidogrel Resistance ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

scholarly journals P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel

2019 ◽  
Vol 14 (6) ◽  
pp. 935-943
Author(s):  
N. M. Vorobyeva
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Coronary Intervention ◽  
Efficacy And Safety ◽  
Acceptable Risk ◽  
Coronary Syndrome ◽  
Risk Of Bleeding ◽  
Percutaneous Coronary ◽  
Ischemic Complications ◽  
Complications And Mortality

The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article. The results of 4 registries in which a comparative analysis of the efficacy and safety of prasugrel with clopidogrel or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves, are considered in detail. The feasibility of replacing clopidogrel to prasugrel during the inpatient treatment of patients with ACS and PCI was evaluated additionally in the MULTIPRAC registry. The results of the registries demonstrate that the use of prasugrel in patients with ACS and PCI is associated with a significant reduction in the risk of ischemic complications and mortality with an acceptable risk of bleeding. At the same time, prasugrel was more effective and safer than clopidogrel and at least was non-inferior to ticagrelor, and according to some registries, even surpasses it in a number of indicators. 

scholarly journals Prasugrel versus ticagrelor in patients with Acute Coronary syndrome treated with percutaneous coronary intervention

2018 ◽  
Vol 6 (6) ◽  
pp. 1945
Author(s):  
Naveen Jamwal ◽  
Shiv Shanker Tripathi
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Acute Coronary Syndromes ◽  
Association Studies ◽  
Coronary Intervention ◽  
Efficacy And Safety ◽  
Target Vessel Revascularization ◽  
Coronary Syndrome ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

Background: No association studies for the efficacy and safety of ticagrelor vs. prasugrel have been published in India. Aim of the study was to compare the safety and efficacy of Prasugrel versus Ticagrelor in Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention.Methods: This retrospective study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute coronary syndromes (ACS) with percutaneous coronary intervention (PCI). A total of 480 patients were studied who had been prescribed either prasugrel or ticagrelor during PCI. Primary end-point was defined as death, re-infarction, urgent target vessel revascularization, serious bleeding requiring transfusion.Results: Primary endpoint was different between the groups receiving prasugrel and ticagrelor (1.2% and 4.0%, respectively; OR (95% CI) 0.38 (0.098; 1.43); P=0.065). Difference was found in the need for urgenttarget vessel revascularization which was significantly lower in the prasugrel group.Rest of the parameters were almost similar with no significant difference.Conclusions: This study comparing prasugrel and ticagrelor shows that Prasugrel is more effective than Ticagrelor in lowering ischemic events in the acute coronary syndromes treated with PCI strategy, especially incidence of stent thrombosis. These observations need further analysis and follow-up.

Sign in / Sign up

Export Citation Format

Share Document